Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Allen Yang Biography and Net Worth

CMO of Xencor

Dr. Yang joined Xencor as senior vice president and chief medical officer in December 2019. Previously he served as senior vice president, head of clinical development and acting chief medical officer at Jazz Pharmaceuticals. Before assuming this role at Jazz, Dr. Yang was the therapeutic area head for hematology and oncology, assembling its clinical development team and overseeing several oncology products, including Erwinaze®, Defitelio® and Vyxeos®. Prior to Jazz, Dr. Yang led clinical development and clinical operations groups at Spectrum Pharmaceuticals, where he was vice president of clinical research. Previously, he held several roles of increasing responsibility at Amgen, including those of global development leader for Aranesp® in oncology and clinical research medical director for Blincyto®, the first bispecific antibody approved by the FDA. Before transitioning to the biopharmaceutical industry, Dr. Yang practiced medicine for several years as an academic oncologist at the University of Southern California, where he led a translational cancer research laboratory. Dr. Yang earned a B.A. in molecular biology from the University of California, Berkeley, and a Ph.D. in biochemistry and an M.D. from the University of Southern California. He completed his medical oncology fellowship at the MD Anderson Cancer Center.

What is Allen Yang's net worth?: The estimated net worth of Allen Yang is at least $1.74 million as of March 9th, 2023. Dr. Yang owns 73,364 shares of Xencor stock worth more than $1,740,194 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Yang may own. Learn More about Allen Yang's net worth.
How do I contact Allen Yang?: The corporate mailing address for Dr. Yang and other Xencor executives is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. Xencor can also be reached via phone at (626) 305-5900 and via email at [email protected]. Learn More on Allen Yang's contact information.
Has Allen Yang been buying or selling shares of Xencor?: Allen Yang has not been actively trading shares of Xencor during the last quarter. Most recently, Allen Yang sold 1,094 shares of the business's stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $29.88, for a transaction totalling $32,688.72. Following the completion of the sale, the chief marketing officer now directly owns 73,364 shares of the company's stock, valued at $2,192,116.32. Learn More on Allen Yang's trading history.
Who are Xencor's active insiders?: Xencor's insider roster includes Bassil Dahiyat (CEO), and Allen Yang (CMO). Learn More on Xencor's active insiders.
Are insiders buying or selling shares of Xencor?: In the last twelve months, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 254,730 shares worth more than $5,453,365.85. The most recent insider tranaction occured on November, 13th when CEO Bassil I Dahiyat sold 3,366 shares worth more than $80,851.32. Insiders at Xencor own 5.2% of the company. Learn More about insider trades at Xencor.
Information on this page was last updated on 11/13/2024.

Allen Yang Insider Trading History at Xencor

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/9/2023	Sell	1,094	$29.88	$32,688.72	73,364
3/6/2023	Sell	4,069	$31.42	$127,847.98	74,458
12/19/2022	Sell	3,737	$27.00	$100,899.00	63,521
3/9/2022	Sell	1,200	$28.94	$34,728.00
12/17/2021	Sell	3,664	$36.62	$134,175.68

Allen Yang Buying and Selling Activity at Xencor

Xencor Company Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Today's Range

Now: $23.72

$23.22

$23.76

50 Day Range

MA: $21.28

$19.43

$23.71

2 Week Range

Now: $23.72

$15.31

$26.84

Volume

546,631 shs

Average Volume

557,956 shs

Market Capitalization

$1.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>